Yuhan Corporation (000100.KS) Stock
Yuhan Corporation

Company profile
Yuhan reported revenue of 2.07 trillion KRW for fiscal year 2024, up 11.2% from fiscal year 2023, and net income of 70.69 billion KRW. That is a net profit margin of 3.4% for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 578.99 billion KRW, up 9.6% from a year before. In Q2 2025 it reported net income of 45.53 billion KRW, against net income of 32.06 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 1.78 trillion KRW in fiscal year 2022 to 2.07 trillion KRW in fiscal year 2024, 7.9% a year on average. Yuhan reports about 2,082 full-time employees.
What stands out
- Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Yuhan Corporation
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
Largest shareholders
- Yuhan Foundation17.24%
- Yuhan Corporation8.19%
- National Pension Service of Korea7.39%
- BlackRock Fund Advisors4.24%
- Sang Ho Lee2.033 %2.03%
Share of the company, as of September 25, 2026
Leadership
- Wook-Je Cho — President, CEO & Executive Director, 70
- Yeul-Hong Kim — President, R&D Director & Executive Director, 66
- Byung-Man Lee — VP, Head of the Mngt. HQ. & Internal Accounting Manager, 67
- Eunhee Park — MD & Director of Legal Affairs, 54
- Joo-Yong Chung — MD & Head of Marketing Department, 58
In the news
How much revenue does Yuhan make?
Yuhan reported 2.07 trillion KRW in revenue for fiscal year 2024, up 11.2% from 1.86 trillion KRW in fiscal year 2023. In Q2 2025 revenue was 578.99 billion KRW.
What companies are similar to Yuhan?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Alteogen Inc. (196170.KQ), Hanmi Pharm. Co., Ltd. (128940.KS), Hanall Biopharma Co., Ltd. (009420.KS), LigaChem Biosciences Inc. (141080.KQ).
How has Yuhan's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 1.62 trillion KRW; FY2021, 1.69 trillion KRW; FY2022, 1.78 trillion KRW; FY2023, 1.86 trillion KRW; FY2024, 2.07 trillion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Yuhan Corporation (000100.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/000100.KS